Edition:
United States

Tenax Therapeutics Inc (TENX.OQ)

TENX.OQ on NASDAQ Stock Exchange Capital Market

0.43USD
14 Dec 2017
Change (% chg)

$0.04 (+9.92%)
Prev Close
$0.39
Open
$0.39
Day's High
$0.44
Day's Low
$0.39
Volume
133,831
Avg. Vol
70,831
52-wk High
$2.64
52-wk Low
$0.31

Summary

Name Age Since Current Position

Ronald Blanck

74 2011 Independent Chairman of the Board

Michael Jebsen

44 2017 President, Interim Chief Executive Officer, Chief Financial Officer

Douglas Hay

2013 Executive Vice President - Regulatory Affairs

Doug Randall

2013 Executive Vice President - Business and Commercial Operations

Paula Bokesch

2015 Chief Medical Officer

James Mitchum

62 Director

Gerald Proehl

58 2014 Director

Anthony DiTonno

68 2011 Independent Director

Gregory Pepin

32 2009 Independent Director

Chris Rallis

61 2011 Independent Director

Ellen Corliss

42 Vice President, Corporate Communications & Investor Relations

Biographies

Name Description

Ronald Blanck

Lieutenant General (Retired) Dr. Ronald R. Blanck, DO, USA, is Independent Chairman of the Board of Oxygen Biotherapeutics, Inc. Dr. Blanck has served as chairman of Martin, Blanck & Associates, a federal health services consulting firm based in Falls Church, VA since January 2010. He began his military career in 1968 as a medical officer and battalion surgeon in Vietnam, retiring 32 years later as a Lieutenant General and Surgeon General of the U.S. Army and commander of the U.S. Army Medical Command. He also served as commander of Walter Reed Medical Center and the North Atlantic Region Medical Command. His background also includes serving as president of the University of North Texas Health Science Center at Fort Worth.

Michael Jebsen

Mr. Michael B. Jebsen, CPA, is President, Interim Chief Executive Officer, Chief Financial Officer of Oxygen Biotherapeutics, Inc. Mr. Jebsen first joined the Company as its Accounting Manager in April 2009, and was elected Chief Financial Officer, Executive Vice President Finance and Administration in August 2009. Mr. Jebsen also served as the Company’s Interim Chief Executive Officer from August 2011 until November 2013. Before joining the Company, he was an auditor with Grant Thornton, LLP from July 2003 through December 2005 and from April 2008 through April 2009. In addition, Mr. Jebsen held various positions, including Chief Ethics Officer, Senior Internal Auditor, and Senior Financial Analyst with RTI International, a non-profit research and development organization, from January 2006 to February 2008. Mr. Jebsen holds a Master of Science in Accounting from East Carolina University and is a Certified Public Accountant, licensed in North Carolina.

Douglas Hay

Dr. Douglas Hay is Executive Vice President - Regulatory Affairs of the Company. Prior to joining the company Dr. Hay was a co-founder of Phyxius Pharma, Inc. where he served as Vice President of Regulatory Affairs. Previously, Dr. Hay lead positions in global regulatory affairs at The Medicines Company and Shire Pharmaceuticals. He spent the majority of his career at Bristol Myers Squibb where he advanced to Vice President, Global Regulatory Sciences. This experience spans drug development (Phase 1-4) in numerous therapeutic areas, including the development of novel biologics and new chemical entities. Dr. Hay’s experience has included responsibility for development projects in virtually all major cardiovascular classes, including development/registration programs for Capoten, Monopril, Avapro, Plavix, and Angiomax. Doug received his AB degree in Biology from University of California, Riverside, MS in biology at California State University, Long Beach, and PhD (physiology emphasis) from Northern Arizona University.

Doug Randall

Mr. Doug Randall is Executive Vice President - Business and Commercial Operations of the Company. Prior to joining the company, Mr. Randall co-founded Phyxius Pharma, Inc. in 2011 where he served as the Chief Commercial Officer. Previously, Mr. Randall served in many senior level executive positions within the pharmaceutical industry, including: Vice President of Commercial Operations at The Medicines Company; Vice President of US Diabetes Marketing at Sanofi-Aventis Pharmaceuticals; and Vice President of Sales at Aventis Pharmaceuticals. Prior to the formation of Aventis Pharmaceuticals in 2000, Mr. Randall served in several senior commercial roles at the former legacy companies (Hoechst Marion Roussel, Marion Merrell Dow, and Marion Laboratories) including: Director of Respiratory Marketing, Director of Cardiovascular marketing, Director of GI/CNS Marketing, Director of Distribution and Pharmacy Markets, and various sales management roles. Mr. Randall started his pharmaceutical career as a sales representative for Marion Laboratories, Inc. in 1982 after earning his B.S. in Pharmacy from the University of Rhode Island.

Paula Bokesch

Dr. Paula Bokesch has been appointed as Chief Medical Officer of the Company. Dr. Bokesch has more than 10 years of drug development experience in acute and critical care indications. Most recently she worked for 5 years as a Senior Medical Director for Drug Development at Cubist Pharmaceuticals, where she served within the Company's programs for Daptomycin, pain, acute/critical care and antibiotics. Dr. Bokesch also served as Global Medical Director for Hospira, where she worked in Medical Affairs and Drug Development within the Precedex and acute/critical care programs. She is also a practicing anesthesiologist at St. Elizabeth's Hospital in Boston, as well as an Affiliate Assistant Professor at Tufts School of Medicine. Dr. Bokesch holds an Medi from the Bowman Gray School of Medicine at Wake Forest University.

James Mitchum

Mr. James Mitchum is a Director of the Company. Mr. Mitchum was recommended to the Corporate Governance and Nominating Committee for consideration as a director nominee by management. Mr. Mitchum has served as the Chief Executive Officer of Heart to Heart International a non-profit humanitarian organization since September 2014. From 2009 to July 2012, Mr. Mitchum served as President of the Americas for EUSA Pharma (USA), Inc., where he oversaw the streamlining of that business as well as the development, FDA approval and successful launch of a pediatric oncology drug in 2011. From 2005 to 2008, Mr. Mitchum served as President and Chief Executive Officer of Enturia, Inc., a privately owned drug-device company, based in Kansas City. From 2003 to 2005, Mr. Mitchum served as the President and Chief Executive Officer of Sanofi-Aventis Group Japan and was Chief Executive for Aventis Pharma UK from 2000 through 2002. He served in many senior financial roles from 1985 until 1999 with Hoechst Marion Roussel (HMR) and predecessor companies and was the Corporate Controller for HMR from 1997 until 2000. Mr. Mitchum currently serves as a director for NephroGenex Inc., a company developing drugs to treat kidney disease, and is a member of its Compensation Committee and chair of its Audit Committee. Mr Mitchum has also served as a director on numerous private company and organization boards. Mr. Mitchum earned an MBA in Business from the University of Tennessee in Knoxville, Tennessee and a Bachelor of Science degree in Business and Math from Milligan College in Johnson City, Tennessee.

Gerald Proehl

Mr. Gerald T. Proehl is Director of Oxygen Biotherapeutics Inc. Mr. Proehl was recently the President and Chief Executive Officer of Santarus, Inc., a company that he helped to found in 1999, and where he led the sale of Santarus to Salix Pharmaceuticals for $2.6 billion in December of 2013. Prior to Santarus, Mr. Proehl was with Hoechst Marion Roussel, Inc., a global pharmaceutical company, where he served in various capacities, including Vice President of Global Marketing. During his career at Hoechst he worked across numerous therapeutic areas, including CNS, cardiovascular, and gastrointestinal. Mr. Proehl was recently appointed to the Board of Directors of Auspex Pharmaceuticals, Inc., a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases. He has also joined the Board of Directors of Sophiris Bio Inc., a publicly traded company developing a late-stage, targeted treatment for benign prostatic hyperplasia. Mr. Proehl holds a B.S. in education from the State University of New York at Cortland, an M.A. in exercise physiology from Wake Forest University and an M.B.A. from Rockhurst University.

Anthony DiTonno

Mr. Anthony A. DiTonno is Independent Director of Oxygen Biotherapeutivs Inc. Since February 2013, Mr. DiTonno has served as Chief Executive Officer of Avantis Medical Systems, Inc., a medical device company that develops and manufactures catheter-based endoscopic devices. From April 2003 until December 2011, Mr. DiTonno was President and Chief Executive Officer of Neurogesx Inc., a biopharmaceutical company based in the San Francisco Bay area. During his time at Neurogesx, Mr. DiTonno also served on its board of directors. Mr. DiTonno has funded companies through a variety of financial arrangements including private and public financings, partnerships and debt. Previously, he was Executive Vice President of Marketing and Sales at Enteric Medical Technologies Inc., which was acquired by Boston Scientific Company; President and Chief Executive Officer of Lifesleep Systems, Inc.; and Vice President and General Manager of Olcassen Pharmaceuticals, which was sold to Watson Laboratories. Early in his career, he held a variety of positions of increasing responsibility at Rorer Group, Inc. (Rhône Poulenc Rorer) and Wyeth Laboratories. Mr. DiTonno received an M.B.A. from Drexel University and a B.S. in Business Administration from St. Joseph’s University.

Gregory Pepin

Mr. Gregory Pepin is Independent Director of Oxygen Biotherapeutics, Inc. From July 2008 until April 2010, he was engaged as a Senior Vice President at Melixia SA (“Melixia”), an investment management company based in Switzerland. In that position he participated in the formation of Vatea Fund, one of company's principal stockholders, and has served as a Managing Director of that fund since June 2009. In May 2010, he co-founded EOS Investment, Ltd. (“EOS”), an investment company based in the Cayman Islands, which serves as investment manager of Vatea Fund, and as investment manager and managing director of OXBT Fund, a fund which holds convertible notes and warrants issued by company. EOS serves as the investment manager and the managing director for two other funds that are not affiliated with the company. In May 2010, he co-founded Independent Wealth Management, SA, an investment management company based in Switzerland, and he has served as a financial analyst for the company since that time. From September 2005 through the end of June 2008, Mr. Pepin was employed as a consultant in finance and insurance by Winter & Associates located in Paris, France. In July 2005, Mr. Pepin earned the degree of Master of Science and Economy, Finance and Actuaries, from HEC Lausanne.

Chris Rallis

Mr. Chris A. Rallis is Independent Director of Oxygen Biotherapeutics Inc. Mr. Rallis is an Executive-in-Residence at Pappas Ventures, a life science venture capital firm based in Durham, NC. From April 2006 until June 2007, he was President and Chief Executive Officer of ImmunoBiosciences, Inc., a vaccine technology company formerly located in Raleigh, NC. He has served as a consultant for Duke University and Panacos Pharmaceuticals, Inc., and is the former President and Chief Operating Officer of Triangle Pharmaceuticals, Inc. (“Triangle”), which was acquired by Gilead Sciences in January 2003 for approximately $465 million. While at Triangle, he participated in 11 equity financings generating gross proceeds of approximately $500 million. He was also primarily responsible for all business development activities which included a worldwide alliance with Abbott Laboratories and the in-licensing of 10 compounds. Earlier, he served in various business development and legal management roles with Burroughs Wellcome, Co. Mr. Rallis serves on the boards of Aeolus Pharmaceuticals and Adherex Technologies and chairs the Audit Committee of both boards. He received his A.B. degree in economics from Harvard College and a J.D. from Duke University.

Ellen Corliss